Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases
Pharmacogenomics · 2023
DOI: 10.2217/pgs-2023-0036 ↗Kurz gefasst
Editorial in der Zeitschrift Pharmacogenomics, 2023. Verfasst von Ingrid Fricke-Galindo und 1 weiteren Autor:innen. Beteiligte Einrichtung: HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, Mexico. Hauptthemen laut MEDLINE: Pharmacogenetics, Respiratory Tract Diseases. Die Arbeit nennt 18 Literaturangaben.
Abstract (Originalsprache)
Tweetable abstract Opportunities for pharmacogenetics implementation in chronic respiratory diseases through the employment of genotype-guided prescriptions in treating nonrespiratory comorbidities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- HLA Laboratory, Instituto Nacional de Enfermedades Respiratorias Ismael Cosio Villegas, Mexico City, 14080, Mexico.
ORCID-Profile: Ingrid Fricke-Galindo, Ramcés Falfán-Valencia
Zitieren
APA
Fricke-Galindo, I., & Falfán-Valencia, R. (2023). Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases. Pharmacogenomics. https://doi.org/10.2217/pgs-2023-0036
Vancouver
Fricke-Galindo I, Falfán-Valencia R. Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases. Pharmacogenomics. 2023. doi:10.2217/pgs-2023-0036
BibTeX
@article{FrickeGalindo2023,
author = {Fricke-Galindo, Ingrid and Falfán-Valencia, Ramcés},
title = {Exploring the Potential Benefits of Pharmacogenomics in Chronic Respiratory Diseases},
journal = {Pharmacogenomics},
year = {2023},
doi = {10.2217/pgs-2023-0036}
}
EUVIMED